Context Therapeutics Inc. financial data

Symbol
CNTX on Nasdaq
Location
Philadelphia, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2,340 % +16.4%
Debt-to-equity 4.53 % -14.3%
Return On Equity -30.93 % +47.4%
Return On Assets -29.59 % +47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91,879,177 shares +22.5%
Common Stock, Shares, Outstanding 91,879,177 shares +22.5%
Entity Public Float 148,200,000 USD +5.2%
Common Stock, Value, Issued 91,879 USD +22.5%
Weighted Average Number of Shares Outstanding, Basic 95,185,187 shares +18.3%
Weighted Average Number of Shares Outstanding, Diluted 95,185,187 shares +18.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 7,674,393 USD +8.7%
Operating Income (Loss) -30,208,407 USD +7.2%
Nonoperating Income (Expense) -66,306 USD -19.8%
Net Income (Loss) Attributable to Parent -26,440,916 USD +12.3%
Earnings Per Share, Basic 0 USD/shares +76.9%
Earnings Per Share, Diluted 0 USD/shares +76.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76,938,183 USD -9.3%
Assets, Current 79,058,817 USD -8.1%
Property, Plant and Equipment, Net 33,721 USD +1.3%
Operating Lease, Right-of-Use Asset 138,622 USD -43.2%
Other Assets, Noncurrent 0 USD -100%
Assets 79,231,160 USD -8.2%
Accounts Payable, Current 2,720,876 USD +1.6%
Employee-related Liabilities, Current 1,091,602 USD +74%
Accrued Liabilities, Current 3,195,918 USD +1.7%
Liabilities, Current 6,035,774 USD +1.6%
Operating Lease, Liability, Noncurrent 21,220 USD -84.9%
Liabilities 6,056,994 USD +1.5%
Retained Earnings (Accumulated Deficit) -117,877,702 USD -28.9%
Stockholders' Equity Attributable to Parent 73,174,166 USD -12.7%
Liabilities and Equity 79,231,160 USD -8.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5,028,381 USD -15.3%
Net Cash Provided by (Used in) Financing Activities -15,268 USD
Net Cash Provided by (Used in) Investing Activities -33,948 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 91,879,177 shares +22.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5,077,597 USD -16.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76,938,183 USD -9.3%
Deferred Tax Assets, Valuation Allowance 24,759,392 USD +49.1%
Deferred Tax Assets, Gross 25,005,599 USD +48.6%
Operating Lease, Liability 100,000 USD -50%
Payments to Acquire Property, Plant, and Equipment 33,948 USD
Operating Lease, Liability, Current 118,980 USD +14.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 9,318,875 USD +20.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital 190,959,989 USD +9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4,055 USD +57.9%
Share-based Payment Arrangement, Expense 1,237,733 USD +42.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%